Home › Research › Prevention and risk
Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications
Hamed SA.. Expert review of clinical pharmacology, 2017-02-22
Topic: Risk, prevention and care in population studies
Plain-language summary
Introduction Diabetes mellitus is a risk for brain injury. Brain injury is associated with acute and chronic hyperglycaemia, insulin resistance, hyperinsulinemia, diabetic ketoacidosis (DKA) and hypoglycaemic events in diabetic patients. Hyperglycemia is a cause of cognitive deterioration, low intelligent quotient, neurodegeneration, brain aging, brain atrophy and dementia. Areas covered: The current review highlights the experimental, clinical, neuroimaging and neuropathological evidence of brain injury induced by diabetes and its associated metabolic derangements. It also highlights the mechanisms of diabetes-induced brain injury. It seems that the pathogenesis of hyperglycemia-induced brain injury is complex and includes combination of vascular disease, oxidative stress, neuroinflammation, mitochondrial dysfunction, apoptosis, reduction of neurotrophic factors, acetylcholinesterase (AChE) activation, neurotransmitters' changes, impairment of brain repair processes, impairment of brain glymphatic system, accumulation of amyloid β and tau phosphorylation and neurodegeneration. The potentials for prevention and treatment are also discussed. Expert commentary: We summarize the risks and the possible mechanisms of DM-induced brain injury and recommend strategies for neuroprotection and neurorestoration. Recently, a number of drugs and substances [in addition to insulin and its mimics] have shown promising potentials against diabetes-induced brain injury. These include: antioxidants, neuroinflammation inhibitors, anti-apoptotics, neurotrophic factors, AChE inhibitors, mitochondrial function modifiers and cell based therapies.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes evidence that diabetes and its metabolic disturbances, including hyperglycaemia and insulin resistance, are associated with brain injury, cognitive deterioration and dementia, and discusses possible mechanisms and prevention strategies. It is a review of evidence and mechanisms, not a trial showing that any treatment prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hamed, S. A. (2017). Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert review of clinical pharmacology. https://doi.org/10.1080/17512433.2017.1293521
Vancouver
Hamed SA. Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert review of clinical pharmacology. 2017. doi:10.1080/17512433.2017.1293521. PMID: 28276776.
BibTeX
@article{hamed2017-28276776,
author = {Hamed, S. A.},
title = {{Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications}},
journal = {Expert review of clinical pharmacology},
year = {2017},
doi = {10.1080/17512433.2017.1293521},
pmid = {28276776},
url = {https://doi.org/10.1080/17512433.2017.1293521}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Brain injury is associated with acute and chronic hyperglycaemia, insulin resistance, hyperinsulinemia, diabetic ketoacidosis (DKA) and hypoglycaemic events in diabetic patients.
Why it matters
This review describes evidence that diabetes and its metabolic disturbances, including hyperglycaemia and insulin resistance, are associated with brain injury, cognitive deterioration and dementia, and discusses possible mechanisms and prevention strategies. It is a review of evidence and mechanisms, not a trial showing that any treatment prevents dementia.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert review of clinical pharmacology) |
| Journal's citation record | 1 / 4 | Expert Review of Clinical Pharmacology: journal h-index 82 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 185 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.8 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 3 / 6 | Cited 5.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 59 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Sherifa Ahmed Hamed: h-index 42 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Assiut University: institution h-index 253 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28276776) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also tagged “small”
900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.